These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 12505685)

  • 1. No reduction of dopamine transporter binding sites in mice following treatment with the TIQ analogue 1-benzyl-1,2,3,4-tetrahydroisoquinoline.
    Ishiwata K; Koyanagi Y; Abe K; Kawamura K; Taguchi K; Saitoh T; Toda J; Sano T
    Brain Res; 2003 Jan; 960(1-2):282-5. PubMed ID: 12505685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of neurotoxicity of TIQ and MPTP and of parkinsonism-preventing effect of 1-MeTIQ by in vivo measurement of pre-synaptic dopamine transporters and post-synaptic dopamine D(2) receptors in the mouse striatum.
    Ishiwata K; Koyanagi Y; Abe K; Kawamura K; Taguchi K; Saitoh T; Toda J; Senda M; Sano T
    J Neurochem; 2001 Nov; 79(4):868-76. PubMed ID: 11723179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of single and repeated administration of 1,2,3,4-tetrahydroisoquinoline analogs on the binding of [11C]raclopride to dopamine D2 receptors in the mouse brain.
    Ishiwata K; Koyanagi Y; Saitoh T; Taguchi K; Toda J; Sano T; Senda M
    J Neural Transm (Vienna); 2001; 108(10):1111-25. PubMed ID: 11725814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of 1,2,3,4,-tetrahydroisoquinoline administration under conditions of CYP2D inhibition on dopamine metabolism, level of tyrosine hydroxylase protein and the binding of [3H]GBR 12,935 to dopamine transporter in the rat nigrostriatal, dopaminergic system.
    Lorenc-Koci E; Antkiewicz-Michaluk L; Wardas J; Zapała M; Wierońska J
    Brain Res; 2004 May; 1009(1-2):67-81. PubMed ID: 15120584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preventative effects of 1-methyl-1,2,3,4-tetrahydroisoquinoline derivatives (
    Munakata H; Ishikawa R; Saitoh T; Kambe T; Chiba T; Taguchi K; Abe K
    Can J Physiol Pharmacol; 2022 Jul; 100(7):594-611. PubMed ID: 35413210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1,2,3,4-Tetrahydroisoquinoline protects terminals of dopaminergic neurons in the striatum against the malonate-induced neurotoxicity.
    Lorenc-Koci E; Gołembiowska K; Wardas J
    Brain Res; 2005 Jul; 1051(1-2):145-54. PubMed ID: 16004976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective dopaminergic neurotoxicity of isoquinoline derivatives related to Parkinson's disease: studies using heterologous expression systems of the dopamine transporter.
    Storch A; Ott S; Hwang YI; Ortmann R; Hein A; Frenzel S; Matsubara K; Ohta S; Wolf HU; Schwarz J
    Biochem Pharmacol; 2002 Mar; 63(5):909-20. PubMed ID: 11911843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of 1,2,3,4-tetrahydroisoquinoline derivatives on dopaminergic spontaneous discharge in substantia nigra neurons in rats.
    Chiba H; Sato H; Abe K; Saito T; Horiguchi Y; Nojima H; Taguchi K
    Pharmacology; 2015; 95(1-2):87-94. PubMed ID: 25633935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single administration of 1-benzyl-1,2,3,4-tetrahydroisoquinoline increases the extracellular concentration of dopamine in rat striatum.
    Katagiri N; Abe K; Kitabatake M; Utsunomiya I; Horiguchi Y; Hoshi K; Taguchi K
    Neuroscience; 2009 Jun; 160(4):820-8. PubMed ID: 19285542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinsonism produced by tetrahydroisoquinoline (TIQ) or the analogues.
    Yoshida M; Ogawa M; Suzuki K; Nagatsu T
    Adv Neurol; 1993; 60():207-11. PubMed ID: 8093578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of tetrahydroisoquinoline (TIQ), one of endogenous substances inducing parkinsonism, on isolated rat vas deferens.
    Koike K; Takayanagi I; Wani S; Yanagita T; Ohta S; Hirobe M
    Gen Pharmacol; 1989; 20(2):259-60. PubMed ID: 2714622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of 1-cyclohexyl- and 1-cyclohexyl-N-propargyl-1,2,3,4-tetrahydroisoquinoline on dopaminergic spontaneous discharge in nigral neurons of rats.
    Abe M; Munakata H; Abe K; Saito T; Horiguchi Y; Nojima H; Taguchi K
    Brain Res Bull; 2016 Mar; 121():201-8. PubMed ID: 26876935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opposite effect of simple tetrahydroisoquinolines on amphetamine- and morphine-stimulated locomotor activity in mice.
    Vetulani J; Nalepa I; Antkiewicz-Michaluk L; Sansone M
    J Neural Transm (Vienna); 2001; 108(5):513-26. PubMed ID: 11459073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions.
    Nagatsu T; Yoshida M
    Neurosci Lett; 1988 Apr; 87(1-2):178-82. PubMed ID: 2898112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical and pathological study of endogenous 1-benzyl-1,2,3,4-tetrahydroisoquinoline-induced parkinsonism in the mouse.
    Abe K; Taguchi K; Wasai T; Ren J; Utsunomiya I; Shinohara T; Miyatake T; Sano T
    Brain Res; 2001 Jul; 907(1-2):134-8. PubMed ID: 11430895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism and penetration through blood-brain barrier of parkinsonism-related compounds. 1,2,3,4-Tetrahydroisoquinoline and 1-methyl-1,2,3,4-tetrahydroisoquinoline.
    Kikuchi K; Nagatsu Y; Makino Y; Mashino T; Ohta S; Hirobe M
    Drug Metab Dispos; 1991; 19(1):257-62. PubMed ID: 1673411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice.
    Callier S; Morissette M; Grandbois M; Pélaprat D; Di Paolo T
    Synapse; 2001 Aug; 41(2):131-8. PubMed ID: 11400179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pinhole SPECT imaging of dopamine transporters correlates with dopamine transporter immunohistochemical analysis in the MPTP mouse model of Parkinson's disease.
    Andringa G; Drukarch B; Bol JG; de Bruin K; Sorman K; Habraken JB; Booij J
    Neuroimage; 2005 Jul; 26(4):1150-8. PubMed ID: 15908232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice.
    Kilbourn MR; Kuszpit K; Sherman P
    Synapse; 2000 Mar; 35(4):250-5. PubMed ID: 10657034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys.
    Goulet M; Morissette M; Grondin R; Falardeau P; Bédard PJ; Rostène W; Di Paolo T
    Synapse; 1999 Jun; 32(3):153-64. PubMed ID: 10340626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.